Results 11 to 20 of about 28,144 (206)
Hospital Pharmacy, 2013 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J +2 more
openaire +4 more sources
PLoS ONEBackgroundApixaban and amiodarone are drugs used for non-valvular atrial fibrillation (NVAF) in routine practice. The evidence about apixaban plasma levels in patients who receive apixaban with amiodarone, including bleeding outcomes, has been limited ...
Sutee Limcharoen +7 more
doaj +2 more sources
Apixaban as a Rare Cause of Leukocytoclastic Vasculitis
Case Reports in Rheumatology, 2020 Apixaban is a rare cause of leukocytoclastic vasculitis (LCV). To our knowledge, there is only one other reported case due to apixaban in the literature. We present a case of apixaban-induced leukocytoclastic vasculitis in a 95-year-old male. He had been
Jenna Spears +4 more
doaj +2 more sources
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
Clinical Pharmacology: Advances and Applications, 2017 Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1 Frank LaCreta1 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA; 2Medical Sciences, Amgen Asia R&D Center ...
Frost C +7 more
doaj +1 more source
Apixaban for extended treatment of venous thromboembolism [PDF]
, 2021 Background: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism.
Raskob, Gary E. +10 more
core +4 more sources
Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
Frontiers in Veterinary Science, 2021 Thrombosis is common in critically ill dogs and causes considerable morbidity and mortality. The direct factor Xa inhibitor apixaban is safe, efficacious, and convenient in humans.
Noelle D. Herrera +5 more
doaj +1 more source
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. [PDF]
PLoS ONE, 2018 Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin.
Xiaoyan Li +11 more
doaj +1 more source
An Observational Study of the Effect of Concomitant Levetiracetam on Apixaban Concentrations in a Hospital Cohort. [PDF]
Clin Transl SciABSTRACT Despite the lack of evidence of a mechanism‐based drug interaction, some professional organizations have advised caution coadministering apixaban and levetiracetam. Eligible patients taking apixaban with or without levetiracetam for any indication for at least 72 h were screened from the electronic medical records.
Riley C +5 more
europepmc +2 more sources
Scientific Reports, 2021 In some clinical situations, measurements of anticoagulant effect of apixaban may be needed. We investigated the inter- and intra-individual apixaban variability in patients with atrial fibrillation and correlated these results with clinical outcome.
Alenka Mavri +7 more
doaj +1 more source